Cinnamaldehyde-Containing Organoarsenic Prodrug with Synergistic Anticancer Activity via Redox Dyshomeostasis

Area of Science:

• Oncology
• Medicinal Chemistry
• Biochemistry

Background:

• Cancer poses a significant global health challenge with high mortality rates.
• Traditional chemotherapy faces increasing failure rates, necessitating novel therapeutic strategies.
• Developing alternative cancer therapies is crucial for improving patient outcomes.

Purpose of the Study:

• To develop a novel small-molecule prodrug, TAO-CA, for enhanced cancer therapy.
• To investigate the mechanism of action of TAO-CA in inducing cancer cell apoptosis.
• To evaluate the efficacy of TAO-CA in inhibiting tumor growth through synergistic redox dyshomeostasis.

Main Methods:

• Conjugation of a trivalent organoarsenical (TAO) with cinnamaldehyde (CA) via an acetal linkage to create the TAO-CA prodrug.
• Activation of the prodrug in a mildly acidic tumor microenvironment.
• Inhibition of thioredoxin reductase (TrxR) activity and reduction of cellular glutathione (GSH) levels.
• Validation through in vitro and in vivo experiments to assess mechanism and efficacy.

Main Results:

• TAO-CA releases parent drugs (TAO and CA) in the acidic tumor environment.
• Simultaneous inhibition of TrxR and reduction of GSH levels induce intracellular redox dyshomeostasis.
• Redox dyshomeostasis leads to cancer cell apoptosis and effective inhibition of tumor growth.
• In vitro and in vivo studies confirm the prodrug's mechanism and therapeutic potential.

Conclusions:

• The TAO-CA prodrug strategy offers a promising approach for cancer therapy.
• Synergistic induction of redox dyshomeostasis is an effective mechanism for cancer treatment.
• Prodrug design holds potential for developing targeted and effective cancer therapeutics.